Research programme: tyrosine kinase inhibitors - Aegera Therapeutics/Redx Pharma

Drug Profile

Research programme: tyrosine kinase inhibitors - Aegera Therapeutics/Redx Pharma

Alternative Names: Bruton's tyrosine kinase inhibitors; Btk/Lck kinase inhibitors; cFMS inhibitors; Colony stimulating factor 1 receptor inhibitors; CSF-1 inhibitors; CSF-1R inhibitors; Lymphocyte-specific protein tyrosine kinase inhibitors

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Aegera Therapeutics
  • Developer Aegera Therapeutics; Redx Pharma
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Lymphocyte specific protein tyrosine kinase p56(lck) inhibitors; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer; Inflammation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Canada
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Canada
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top